Venetoclax in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||07/10/2020|
|Rapid review completed||22/10/2020|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax in combination with obinutuzumab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by HSE||27/10/2020|
|Pre-submission consultation with Applicant||30/11/2020|
|Current Status||Awaiting HTA submission from Applicant|